GRAL Graildata gap · 52% coveragelimited data
Health Care · Services-Medical Laboratories · close $117.81 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Grail (GRAL) has a ThetaGrade House Rating of 41/100 (grade D), ranking #84 of 150 in Health Care. Its strongest pillars are balance sheet (91) and growth (62); its weakest is profitability (3). Data gap: 7 factors without usable data, so 52% of the method weight is covered. TTM revenue growth is 23.1% and operating margin -338.4%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), 4Q gross-margin change, Net debt / EBITDA, Interest coverage, P/E (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 52% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 62| Revenue growth YoY (TTM) (22.2%) | 23.1% | 76 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | -2.4% | 35 |
Profitability
weight 18.5% (→20.0%) · 3| Operating margin (20.0%) | -338.4% | 3 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→20.0%) · 91| Net debt / EBITDA (0.0%)data gap | — | — |
| Current ratio (20.0%) | 10.95 | 91 |
| Interest coverage (0.0%)data gap | — | — |
Cash flow
weight 12.33% (→13.3%) · 6| FCF margin (6.7%) | -203.8% | 5 |
| FCF yield (6.7%) | -5.7% | 6 |
Valuation
weight 12.33% (→13.3%) · 6| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (13.3%) | 31.50× | 6 |
Technicals (EOD)
| RSI(14) | 48.6 |
| EMA 9 / 21 | 132.77 / 124.90 |
| 200-day SMA | 75.94 |
| Volume vs 20d avg | 0.83× |
| 20-day return | 56.8% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITBalance-sheet stress: negative free cash flow (latest FY)
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Operating income: OperatingIncomeLoss · D&A: Depreciation · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like GRAL's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is GRAL's House Rating?
- GRAL scores 41 out of 100 (grade D) as of 2026-10-16, ranking #84 of 150 Health Care stocks we cover.
- What do analysts say about GRAL?
- We do not have enough analyst-sentiment data to score this stock.
- When does GRAL report earnings next?
- GRAL's next earnings report is estimated for about 2026-11-11 (window 2026-11-04 to 2026-11-18), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is GRAL a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology